Source-grounded facts extracted from Galera Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Galera Therapeutics, Inc.: Adopted Amended and Restated Bylaws providing written consent right consistent with charter amendment (effective 2026-05-12).
“Also on May 12, 2026, the Board of Directors of the Company approved and adopted Amended and Restated Bylaws of the Company, effective immediately. The Amended and Restated Bylaws provide stockholders with a written consent right and sets forth certain procedures associated therewith, consistent with the Written Consent Charter Amendment.”
Galera Therapeutics, Inc.: Provided stockholders with a right to act by written consent (effective 2026-05-12).
“On May 12, 2026, the Company filed a Certificate of Amendment to the Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to provide stockholders with a right to act by written consent (the “Written Consent Charter Amendment”).”
Galera Therapeutics, Inc.: Increased authorized common stock from 200 million to 400 million shares (effective 2026-05-11).
“On May 11, 2026, Galera Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 200 million shares to 400 million shares (the “Stock Increase Charter Amendment”).”
Galera Therapeutics, Inc. shareholders approved Approval of Charter Amendment to Effect a Reverse Stock Split at a ratio between 1:75 and 1:200, if and when determined by the Board at the 2026-05-08 meeting.
“Proposal 7—Approval of Charter Amendment to Effect a Reverse Stock Split: Votes For Votes Against Abstentions 121,087,262 2,639,613 31,517”
Galera Therapeutics, Inc. shareholders approved Approval of Charter Amendment to Provide Written Consent Right at the 2026-05-08 meeting.
“Proposal 6—Approval of Charter Amendment to Provide Written Consent Right: Votes For Votes Against Abstentions Broker Non-Votes 112,456,777 417,500 6,166 10,877,949”
Galera Therapeutics, Inc. shareholders approved Approval of Charter Amendment to Increase Authorized Capital Stock from 200 million shares to 400 million shares at the 2026-05-08 meeting.
“Proposal 5—Approval of Charter Amendment to Increase Authorized Capital Stock: Votes For Votes Against Abstentions 120,916,020 2,745,505 96,867”
Galera Therapeutics, Inc. shareholders approved Advisory Vote on Frequency of Future Say-On-Pay Votes (every one year) at the 2026-05-08 meeting.
“Proposal 4—Advisory Vote on Frequency of Future Say-On-Pay Votes: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 108,127,837 64,666 3,611,866 1,076,074 10,877,949”
Galera Therapeutics, Inc. shareholders approved Approval of compensation paid to the Company’s named executive officers (Say-on-Pay) at the 2026-05-08 meeting.
“Proposal 3—Say-on-Pay Vote: Votes For Votes Against Abstentions Broker Non-Votes 108,167,385 3,690,210 1,022,848 10,877,949”
Galera Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-08 meeting.
“Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm: Votes For Votes Against Abstentions 121,742,195 1,961,191 55,006”
Galera Therapeutics, Inc. shareholders approved Election of Directors at the 2026-05-08 meeting.
“At the combined 2025 and 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”) of Galera Therapeutics, Inc. (the “ Company ”) held on May 8, 2026, the Company’s stockholders (i) elected (A) one Class III director to the board of directors of the Company (the “ Board ”), to serve until the Company’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified, and (B) two Class I directors to the Board, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified”
Galera Therapeutics, Inc. entered into Agreement and Plan of Merger with Obsidian Therapeutics, Inc., Gazelle Parent, Inc., Onyx MergerSub, Inc., Gazelle Merger Subsidiary, Inc. (effective 2026-04-14).
“On April 14, 2026, Galera Therapeutics, Inc., a Delaware corporation (“Galera”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Galera, Obsidian Therapeutics, Inc., a Delaware corporation (“Obsidian”), Gazelle Parent, Inc., a Delaware corporation (“Parent”), Onyx MergerSub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“Obsidian Merger Sub”), and Gazelle Merger Subsidiary, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“Galera Merger Sub”).”
Galera Therapeutics, Inc.: Amended Series B Preferred Stock Certificate of Designation to allow board discretion to convert shares to Common Stock based on Conversion Ratio (effective 2026-02-12).
“On February 12, 2026, Galera Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of Delaware.”
Galera Therapeutics, Inc.: Galera intends to file a Certificate of Elimination to eliminate the Series A Junior Participating Preferred Stock designation, returning those shares to authorized but unissued preferred stock (effective 2024-12-31).
“Galera intends to file a Certificate of Elimination eliminating from its Certificate of Incorporation, as amended, the designation of certain shares of its preferred stock as Series A Junior Participating Preferred Stock, which had been designated for potential use in connection with the Rights Agreement.”
Galera Therapeutics, Inc. completed an acquisition involving Nova Pharmaceuticals, Inc. for 119,318.285 shares of preferred stock, par value $0.001 per share, designated as Series B Non-Voting Convertible Preferred Stock (closed 2024-12-30).
“(17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share GRTX OTC Pink Market Series A Junior Participating Preferred Stock (Purchase Rights) N/A OTC Pink Market Indicate by check mark whether the registrant is an”
Christopher Degnan departed as Chief Financial Officer at Galera Therapeutics, Inc..
“On August 8, 2024, the Company notified Christopher Degnan, the Company’s Chief Financial Officer and principal financial officer, that his position is being eliminated, effective August 31, 2024, in order to save costs as the Company moves forward with the dissolution of the Company, as described below.”
Robert A. Beardsley departed as Chief Operating Officer at Galera Therapeutics, Inc..
“On June 4, 2024, Galera Therapeutics, Inc. (the “Company”) notified Robert A. Beardsley, Ph.D., the Company’s Chief Operating Officer, that his position is being eliminated in order to save costs as the Company continues to undertake a comprehensive review of strategic alternatives for both the Company and its portfolio of dismutase mimetics.”
Galera Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $(4.4) million, or $(0.08) per share, EPS $(0.08) per share.
“Galera reported a net loss of $(4.4) million, or $(0.08) per share, for the first quarter of 2024, compared to a net loss of $(17.7) million, or $(0.50) per share, for the same period in 2023.”
Galera Therapeutics, Inc.: Board approved a Certificate of Designation creating Series A Junior Participating Preferred Stock in connection with the adoption of a stockholder rights agreement (effective 2024-05-03).
“In connection with the adoption of the Rights Agreement described in Item 3.03 of this Current Report, the Board approved a Certificate of Designation of Series A Junior Participating Preferred Stock, which designates the rights, preferences and privileges of 200,000 shares of a series of the Company’s preferred stock, par value $0.001 per share, designated as Series A Junior Participating Preferred Stock.”
Galera Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates”
Galera Therapeutics, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).
“March 26, 2024, the Company received a letter from the Staff indicating that the Company has not regained compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum MVPHS Requirement”), and that, unless the Company requests a hearing before a Panel to appeal Nasdaq’s delisting determination by 4:00 p.m. Eastern Time on April 2, 2024, trading of the Company’s common stock will be suspended at the opening of business on April 3, 2024, and the C”
Galera Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income $(15.1) million, EPS $(0.33) per share.
“Galera reported a net loss of $(15.1) million, or $(0.33) per share”
Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).
“September 25, 2023, Galera Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the Company is no longer in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum MVPHS Requirement”). The Notice has no effect at this time on the listing of the Company’s common stock, par value $0.001 per share (“Common Stock”), which continues to trade on The Nasd”
Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“September 22, 2023, Galera Therapeutics, Inc. (the “Company”) received two written notices (the “Notices”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that (i) the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “Minimum MVLS Requirement”) and (ii) for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed bel”
Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
“September 22, 2023, Galera Therapeutics, Inc. (the “Company”) received two written notices (the “Notices”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that (i) the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “Minimum MVLS Requirement”) and (ii) for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed bel”
Galera Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income a net loss of $(20.7) million, or $(0.48) per share, EPS $(0.48) per share.
“Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the second quarter ended June 30, 2023, and provided recent corporate updates.”
Mark Bachleda departed as Chief Commercial Officer at Galera Therapeutics, Inc..
“On August 9, 2023, Mark Bachleda, Pharm.D., the Company’s Chief Commercial Officer, was informed that his position was being eliminated in connection with the Workforce Reduction.”
Galera Therapeutics, Inc. reported preliminary financial results for the three months ended June 30, 2023.
“Preliminary Financial Results - Cash Balance as of June 30, 2023 On August 9, 2023, Galera Therapeutics, Inc. (the “Company”) announced that, based upon preliminary estimates and information available to the Company, it expects to report that it had cash, cash equivalents and short-term investments of approximately $38.8 million as of June 30, 2023.”
Galera Therapeutics, Inc. announced a restructuring with charges of approximately $2.0 to $2.5 million affecting the Company’s current workforce (22 employees, approximately 70% of headcount) (22 employees, or approximately 70% of the Company’s headcount).
“The decision was based on cost-reduction initiatives intended to reduce operating expenses. The Company currently estimates that it will incur charges of approximately $2.0 to $2.5 million in connection with the Workforce Reduction, primarily consisting of severance payments, employee benefits and related costs. The Company expects that the majority”
Galera Therapeutics, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-14 meeting.
“Item 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 28,291,469 9,547 11,161 0”
Galera Therapeutics, Inc. shareholders approved Election of two Class I Directors to serve until the 2026 Annual Meeting of Stockholders at the 2023-06-14 meeting.
“Item 1 — Election of two Class I Directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Michael Powell, Ph.D. 15,141,283 4,723,401 8,447,493 Linda West 15,219,991 4,644,693 8,447,493”
Galera Therapeutics, Inc. reported financial results for quarter ended March 31, 2023.
“On May 11, 2023, Galera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2023.”
Galera Therapeutics, Inc. reported the year ended December 31, 2022 results: net income $(62.2) million, or $(2.30) per share, EPS $(2.30) per share.
“Galera reported a net loss of $(62.2) million, or $(2.30) per share, for the year ended December 31, 2022”
Galera Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: net income $(16.2) million, or $(0.58) per share, EPS $(0.58) per share.
“Galera reported a net loss of $(16.2) million, or $(0.58) per share, for the fourth quarter of 2022”
Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
“December 6, 2022, Galera Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company has not regained compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”), and that, unless the Company requests a hearing before a Nasdaq Hearings Panel (“Panel”) to appeal Nasdaq’s delisting determination by 4:00 p.m. Eastern Time on December 13”
Galera Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income ($16.0) million, or $(0.60) per share, EPS $(0.60) per share.
“Galera reported a net loss of ($16.0) million, or $(0.60) per share, for the third quarter of 2022, compared to a net loss of $(22.6) million, or $(0.86) per share, for the same period in 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.